Women who don't have BRCA mutations could have other high-risk genes that affect treatment choices
by sestelle on Sat Dec 01, 2012 11:25 PM
My friend was diagnosed with Stage IV metastasized pancreatic cancer with 6 tumors on the liver on 7/13/2012. On August 13, his oncologist started to treat him with folfirinex. Since then his CA9-19 and CEA markers continue to rise substantially and the cancer has spread to the spine. His oncologist is recommending that he switch to Gemar as it does not appear as if the Folfirinex is slowing the spread of the cancer.
Has anyone experienced something similar?
When you track a discussion, you will get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to track this discussion?
If you stop tracking this discussion, you will no longer get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to stop tracking this discussion?
We care about your feedback. Let us know how we can improve your CancerCompass experience.